Genencor International, Inc.

Danisco US Inc.

Other

The Procter Gamble Company

University of California

Finnfeeds International Ltd.

Volker Schellenberger

James T. Kellis

Christian Paech

Donald P. Naki

Joanne Nadherny

Ayrookaran J. Poulose

Robert M. Caldwell

Katherine D. Collier

Andre C. Baeck

Katherine D Collier

James T Kellis, Jr

Ayrookaran J Poulose

Donald P Naki

David Aaron Estell

Kathleen A Clarkson

Robert Mark Caldwell

Edmund A Larenas

Christian G Paech

Scott Douglas Power

Brian Frederick Schmidt

Michael C Ward

Timothy Fowler

Neelam S Amin

Gudrun Vogtentanz

Melodie Estabrook

Bryan P Fox

Alfred Busch

Michael Stanford Showell

Chanchal Kumar Ghosh

Andr&eacute; Cesar Baeck

Ryohei Ohtani

Marc Kolkman

Anita Van Kimmenade

Jeffrey V Miller

Michael Richard Bedford

Andrew J Morgan

Grant C Ganshaw

Hans De Nobel

James T Kellis

Glenn Steven Ward

Philip Frank Souter

Jian Yao

Olga V Selifonova

Thomas P Graycar

Luis Gustavo Cascao-Pereira

Thomas B Morrison

Katherine Augustyn

You-Lo Hsieh

Edwin Lee

Nicholas Leiva

Adam C Kean

Mary Michelle Hartzell

André Cesar Baeck

Andre C Baeck

Manoj N Kumar

Anthony G Day

Benjamin S Bower

Andre Cesar Baeck

Michael Jay Pepsin

Matthew Grant Boston

Christopher James Murray

William Albert Cuevas

Joshua Roy Basler

Viktor Alekseyev

Alexander Pisarchik

Euan John Magennis

Edward M Concar

Luis Gustavo Cascão-Pereira

Phillip Frank Souter

Robert M Caldwell

Andr&eacute;Cesar Baeck

Raj Lad

Gudrun Vogentanz

Moira B Kelly

Ayrookaran Joseph Poulose

Viktor Yuryevich Alekseyev

James T Kellis Jr

Jr James T Kellis

Christian Adams

Donald P c/o Genencor International Inc Naki

James T c/o Genencor International Inc Kellis

André C Baeck

The present invention provides serine protease variants produced there from. Specifically, the present invention provides serine protease variants having one or more substitutions as compared to a reference serine protease. In addition, the present invention provides compositions comprising these serine protease variants. In some embodiments, the present invention provides cleaning compositions comprising at least one of these serine protease variants.

[object Object]

The present invention provides serine protease variants, more specifically subtilisin variants produced there from. Specifically, the present invention provides serine protease variants, more specifically subtilisin variants having one or more substitutions as compared to a reference serine protease. In addition, the present invention provides compositions comprising these serine protease variants, more specifically subtilisin variants. In some embodiments, the present invention provides cleaning compositions comprising at least one of these serine protease variants, more specifically subtilisin variants.

Compositions and methods comprising serine protease variants

The present invention provides peptides and supported peptides for treating various diseases and conditions. In particularly preferred embodiments, the present invention provides compositions and methods for personal care. In some embodiments the present invention provides compositions for use in skin and/or hair care, as well as cosmetic compositions. IN alternative particularly preferred embodiments, the present invention provides peptides and supported peptides for treating diseases of the skin, such as rosacea. In some particularly preferred embodiments, the supported peptides of the present invention are anti-VEGF peptides. In alternative particularly preferred embodiments, the anti-VEGF peptides are expressed on a scaffold protein. In some most preferred embodiments, the scaffold protein comprises BBI.

Peptide personal care compositions and methods for their use

The present invention relates to modified variant Bowman Birk Protease Inhibitor proteins (BBPIs) that comprise peptides that bind target proteins, and that are further modified to have greater protease inhibitory activity and/or be produced at greater yields than the unmodified BBPIs. The invention encompasses polynucleotide constructs and expression vectors containing polynucleotide sequences that encode the modified variant BBPIs, the transformed host cells that express and produce the modified variant BBPIs, the modified variant BBPI proteins, the compositions comprising the modified variant BBPIs, and the methods for making and using the modified variant BBPIs in personal care.

Modified variant Bowman Birk protease inhibitors

The use is provided composition as a feed additive which comprises one or more endoglucanases, and 0-20% by weight, based upon the content of cellulase proteins in the composition, of a cellobiohydrolase. The endoglycanases may be one or more of EGI, EGII, EGIII and any functionally active derivative of any thereof. Such endoglucanases may be obtained from a genetically modified strain of the fungus. Also provided is an enzyme-based feed additive which comprises EGI and/or EGII which lack the cellulose binding domain, and 0-20% by weight, based upon the content of cellulase proteins in the additive, of a cellobiohydrolase. A further enzyme-based feed additive is provided which comprises a cereal-based carrier, one or more endoglucanases, and 0-20% by weight, based upon the content of cellulase proteins in the additive, of a cellobiohydrolase.

Enzyme feed additive and animal feed including it

An evolvable production strain ofexhibiting continuous or high level expression during protein evolution is described. An evolvedpstS promoter facilitates screening and production of secreted proteins.

Modified variant Bowman Birk Protease Inhibitors

Modified variant bowman birk protease inhibitors

The present invention relates to compositions that comprise modified variant Bowman Birk Protease Inhibitor proteins (BBPIs). The modified variant BBPIs comprise peptides that bind target proteins, and that are further modified to have greater protease inhibitory activity and/or be produced at greater yields than the unmodified BBPIs. The invention encompasses the compositions comprising the modified variant BBPIs, and the methods for making and using the compositions in personal care.

Personal care compositions comprising modified variant Bowman Birk Protease Inhibitors

The present invention provides compositions and methods related to expression of protease inhibitors and variants thereof in bacterial species. The present invention further provides fusion nucleic acids, vectors, fusion polypeptides, and processes for obtaining the protease inhibitors.

Compositions comprising bowman-birk protease inhibitors and variants thereof

Biomolecular conjugates are provided which comprise the conjugation product of a repeat sequence protein polymer and at least one active agent. Additional aspects provide methods for their manufacture and various industrial and consumer applications.

Repeat sequence protein polymer active agent congjugates, methods and uses

The present invention provides compositions and methods related to the expression of Bowman-Birk protease inhibitors and variants thereof in bacterial species. The present invention further provides fusion nucleic acids, vectors, fusion polypeptides, and processes for obtaining the Bowman-Birk protease inhibitors.

Bacterial expression of bowman-birk protease inhibitors and variants thereof

Novel protease variants derived from the DNA sequences of naturally-occurring or recombinant non-human proteases are disclosed. The variant proteases, in general, are obtained by in vitro modification of a precursor DNA sequence encoding the naturally-occurring or recombinant protease to generate the substitution of a plurality of amino acid residues in the amino acid sequence of a precursor protease. Protease variants are provided that contain substitutions of the amino acids at one or more residue positions so that the substitution alters the charge at that position to make the charge more negative or less positive compared to a precursor protease and thus the protease variant is more effective in a low detergent concentration system than a precursor protease. Also provided are protease variants containing substitutions of the amino acids at one or more residue positions so that the substitution alters the charge at that position to make the charge more positive or less negative compared to a precursor protease and thus the protease variant is more effective in a high detergent concentration system than a precursor protease. Protease variants are provided that contain substitutions of the amino acids at one or more residue positions so that the substitution alters the charge at that position to make the charge more negative or less positive compared to a precursor protease and thus the protease variant is more effective in a medium detergent concentration system than a precursor protease. Also provided are protease variants containing substitutions of the amino acids at one or more residue positions so that the substitution alters the charge at that position to make the charge more positive or less negative compared to a precursor protease and thus the protease variant is more effective in a medium detergent concentration system than a precursor protease. Further provided is a method of producing a protease variant that is more effective in a low detergent concentration system, medium detergent concentration system and high detergent concentration system than a precursor protease.

Multiply-substituted protease variants with altered net charge for use in detergents

Growing community of inventors

Los Altos, CA, United States of America

Katherine D Collier